Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer after docetaxel failure
CTR20132372Phase 3Completed
- Sponsor
- Patheon
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Patheon. Started Jan 2015; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20132372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132372.